

## COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022  
Data Lock Date: 20-Apr-2022 18:30:04

All UK spontaneous ADR reports for COVID-19 Vaccine AstraZeneca received from Isle of Man up to and including 20/04/2022.

A report of a suspected ADR to the Yellow Card Scheme does not necessarily mean that it was caused by the vaccine, only that the reporter has a suspicion it may have. Underlying or previously undiagnosed illness unrelated to vaccination can also be factors in such reports. The relative number and nature of reports should therefore not be used to compare the safety of the different vaccines. All reports are kept under continual review in order to identify possible new risks.

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022  
Earliest Reaction Date: 21-Mar-2020

Data Lock Date: 20-Apr-2022 18:30:04  
MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Blood disorders</b>		
<i><b>Coagulopathies</b></i>		
Antiphospholipid syndrome	1	0
<i><b>Lymphatic system disorders NEC</b></i>		
Lymph node pain	2	0
Lymphadenopathy	14	0
<i><b>Polycythaemia (excl rubra vera)</b></i>		
Stress polycythaemia	1	0
<i><b>Thrombocytopenias</b></i>		
Thrombocytopenia	2	0
<b>Blood disorders SOC TOTAL</b>	<b>20</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Cardiac disorders</b>		
<i>Cardiac signs and symptoms NEC</i>		
Palpitations	13	0
<i>Ischaemic coronary artery disorders</i>		
Angina pectoris	3	0
<i>Noninfectious myocarditis</i>		
Myocarditis	1	0
<i>Rate and rhythm disorders NEC</i>		
Extrasystoles	1	0
Tachycardia	2	0
<i>Supraventricular arrhythmias</i>		
Atrial fibrillation	2	0
<i>Ventricular arrhythmias and cardiac arrest</i>		
Cardiac arrest	1	0
<b>Cardiac disorders SOC TOTAL</b>	<b>23</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Ear disorders</b>		
<i>Ear disorders NEC</i>		
Ear pain	7	0
<i>Hyperacusia</i>		
Hyperacusis	3	0
<i>Inner ear signs and symptoms</i>		
Tinnitus	8	0
Vertigo	10	0
Vertigo positional	1	0
<b>Ear disorders SOC TOTAL</b>	<b>29</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Endocrine disorders</b>		
<i>Adrenal gland disorders NEC</i>		
Haemorrhagic adrenal infarction	1	0
<b>Endocrine disorders SOC TOTAL</b>	<b>1</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022  
 Earliest Reaction Date: 21-Mar-2020

Data Lock Date: 20-Apr-2022 18:30:04  
 MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Eye disorders</b>		
<i><b>Choroid and vitreous structural change, deposit and degeneration</b></i>		
Vitreous floaters	1	0
<i><b>Eyelid movement disorders</b></i>		
Eyelid ptosis	1	0
<i><b>Iris and uveal tract infections, irritations and inflammations</b></i>		
Iritis	1	0
<i><b>Lid, lash and lacrimal structural disorders</b></i>		
Eyelid skin dryness	1	0
<i><b>Ocular disorders NEC</b></i>		
Eye pain	11	0
<i><b>Ocular infections, inflammations and associated manifestations</b></i>		
Eye pruritus	2	0
<i><b>Ocular sensation disorders</b></i>		
Asthenopia	2	0
Photophobia	3	0
<i><b>Visual disorders NEC</b></i>		
Diplopia	1	0
Dysmetropsia	1	0
Photopsia	2	0
Vision blurred	8	0
<i><b>Visual impairment and blindness (excl colour blindness)</b></i>		
Blindness	2	0
Visual impairment	3	0
<b>Eye disorders SOC TOTAL</b>	<b>39</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022  
Earliest Reaction Date: 21-Mar-2020

Data Lock Date: 20-Apr-2022 18:30:04  
MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Gastrointestinal disorders</b>		
<i>Abdominal findings abnormal</i>		
Gastrointestinal sounds abnormal	1	0
<i>Colitis (excl infective)</i>		
Crohn's disease	1	0
Inflammatory bowel disease	1	0
<i>Dental pain and sensation disorders</i>		
Dental discomfort	1	0
Hyperaesthesia teeth	1	0
Toothache	2	0
<i>Diarrhoea (excl infective)</i>		
Diarrhoea	29	0
<i>Dyspeptic signs and symptoms</i>		
Dyspepsia	2	0
Eructation	1	0
<i>Faecal abnormalities NEC</i>		
Faeces hard	1	0
<i>Flatulence, bloating and distension</i>		
Abdominal distension	1	0
Flatulence	2	0
<i>Gastrointestinal and abdominal pains (excl oral and throat)</i>		
Abdominal pain	14	0
Abdominal pain lower	2	0
Abdominal pain upper	12	0
Oesophageal pain	1	0
<i>Gastrointestinal atonic and hypomotility disorders NEC</i>		
Constipation	1	0
Intestinal dilatation	1	0
<i>Gastrointestinal dyskinetic disorders</i>		
Bowel movement irregularity	1	0
Change of bowel habit	1	0
Dyschezia	1	0
<i>Gastrointestinal signs and symptoms NEC</i>		
Abdominal discomfort	2	0
Dysphagia	2	0
<i>Gastrointestinal vascular occlusion and infarction</i>		
Intestinal ischaemia	1	0
Mesenteric arterial occlusion	1	0
Mesenteric artery thrombosis	1	0
Visceral venous thrombosis	1	0
<i>Intestinal haemorrhages</i>		
Rectal haemorrhage	1	0
<i>Nausea and vomiting symptoms</i>		
Nausea	100	0
Retching	1	0
Vomiting	33	0
<i>Oral dryness and saliva altered</i>		
Dry mouth	2	0
Lip dry	1	0
Salivary hypersecretion	1	0
<i>Oral soft tissue disorders NEC</i>		
Chapped lips	2	0
<i>Oral soft tissue signs and symptoms</i>		
Hypoaesthesia oral	4	0

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022  
 Earliest Reaction Date: 21-Mar-2020

Data Lock Date: 20-Apr-2022 18:30:04  
 MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Gastrointestinal disorders</b>		
<i>Gastrointestinal disorders cont'd</i>		
Paraesthesia oral	4	0
<b><i>Oral soft tissue swelling and oedema</i></b>		
Lip swelling	2	0
<b><i>Stomatitis and ulceration</i></b>		
Aphthous ulcer	1	0
Mouth ulceration	1	0
<b><i>Tongue signs and symptoms</i></b>		
Glossodynia	2	0
Swollen tongue	3	0
Tongue coated	1	0
Tongue discolouration	1	0
Tongue spasm	1	0
<b>Gastrointestinal disorders SOC TOTAL</b>	<b>246</b>	<b>0</b>



## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>General disorders</b>		
<i><b>Asthenic conditions</b></i>		
Asthenia	18	0
Fatigue	140	0
Malaise	28	0
<i><b>Complications associated with device NEC</b></i>		
Medical device site joint pain	1	0
<i><b>Febrile disorders</b></i>		
Pyrexia	125	0
<i><b>Feelings and sensations NEC</b></i>		
Chills	107	0
Feeling abnormal	7	0
Feeling cold	15	0
Feeling hot	7	0
Feeling of body temperature change	4	0
Hangover	2	0
Hunger	1	0
Temperature intolerance	1	0
Thirst	5	0
<i><b>Gait disturbances</b></i>		
Gait disturbance	2	0
Loss of control of legs	1	0
<i><b>General signs and symptoms NEC</b></i>		
Illness	6	0
Influenza like illness	39	0
Local reaction	1	0
Peripheral swelling	21	0
Swelling	7	0
Swelling face	1	0
<i><b>Inflammations</b></i>		
Inflammation	5	0
<i><b>Injection site reactions</b></i>		
Injection site erythema	2	0
Injection site extravasation	1	0
Injection site mass	2	0
Injection site pain	16	0
Injection site rash	1	0
Injection site scab	1	0
<i><b>Mass conditions NEC</b></i>		
Mass	1	0
<i><b>Oedema NEC</b></i>		
Oedema peripheral	2	0
<i><b>Pain and discomfort NEC</b></i>		
Axillary pain	1	0
Chest discomfort	2	0
Chest pain	19	0
Discomfort	5	0
Pain	41	0
Tenderness	2	0
<i><b>Therapeutic and nontherapeutic responses</b></i>		
Drug ineffective	2	0
<i><b>Vaccination site reactions</b></i>		
Vaccination site erythema	3	0
Vaccination site hypoaesthesia	1	0

# Case Series Drug Analysis Print

## Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>General disorders</b> General disorders cont'd		
Vaccination site mass	1	0
Vaccination site movement impairment	2	0
Vaccination site pain	1	0
Vaccination site swelling	1	0
Vaccination site warmth	2	0
<b>General disorders SOC TOTAL</b>	<b>653</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Hepatic disorders</b>		
<i>Hepatic and hepatobiliary disorders NEC</i>		
Liver disorder	1	0
<i>Hepatocellular damage and hepatitis NEC</i>		
Hepatitis acute	1	0
<i>Obstructive bile duct disorders (excl neoplasms)</i>		
Sphincter of Oddi dysfunction	2	0
<b>Hepatic disorders SOC TOTAL</b>	<b>4</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022  
Earliest Reaction Date: 21-Mar-2020

Data Lock Date: 20-Apr-2022 18:30:04  
MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Immune system disorders</b>		
<i>Allergic conditions NEC</i>		
Allergic oedema	1	0
Hypersensitivity	2	0
<i>Anaphylactic and anaphylactoid responses</i>		
Anaphylactic reaction	3	0
<i>Atopic disorders</i>		
Seasonal allergy	1	0
<i>Immune and associated conditions NEC</i>		
Bacille Calmette-Guerin scar reactivation	1	0
Sensitisation	1	0
<b>Immune system disorders SOC TOTAL</b>	<b>9</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022  
Earliest Reaction Date: 21-Mar-2020

Data Lock Date: 20-Apr-2022 18:30:04  
MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Infections</b>		
<i><b>Bacterial infections NEC</b></i>		
Bacterial infection	1	0
<i><b>Candida infections</b></i>		
Vulvovaginal candidiasis	1	0
<i><b>Coronavirus infections</b></i>		
COVID-19	2	0
Suspected COVID-19	1	0
<i><b>Coxiella infections</b></i>		
Q fever	1	0
<i><b>Herpes viral infections</b></i>		
Herpes zoster	4	0
Oral herpes	2	0
<i><b>Infections NEC</b></i>		
Infection	5	0
Vaccination site infection	1	0
<i><b>Influenza viral infections</b></i>		
Influenza	35	0
<i><b>Lower respiratory tract and lung infections</b></i>		
Pneumonia	2	0
<i><b>Retroviral infections</b></i>		
HIV infection	1	0
<i><b>Sepsis, bacteraemia, viraemia and fungaemia NEC</b></i>		
Sepsis	1	0
<i><b>Upper respiratory tract infections</b></i>		
Nasopharyngitis	9	0
Pharyngitis	1	0
Sinusitis	1	0
<i><b>Urinary tract infections</b></i>		
Urinary tract infection	1	0
<i><b>Viral infections NEC</b></i>		
Sweating fever	4	0
Viral infection	1	0
<b>Infections SOC TOTAL</b>	<b>74</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Injuries</b>		
<i>Exposures associated with pregnancy, delivery and lactation</i>		
Maternal exposure during breast feeding	6	0
<i>Medication errors, product use errors and issues NEC</i>		
Inadequate aseptic technique in use of product	1	0
<i>Muscle, tendon and ligament injuries</i>		
Muscle rupture	1	0
<i>Non-site specific procedural complications</i>		
Injection related reaction	4	0
<i>Overdoses NEC</i>		
Intentional overdose	1	0
<i>Product prescribing errors and issues</i>		
Contraindicated product prescribed	1	0
<i>Site specific injuries NEC</i>		
Limb injury	1	0
<i>Skin injuries NEC</i>		
Contusion	4	0
<b>Injuries SOC TOTAL</b>	<b>19</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Investigations</b>		
<i>Central nervous system imaging procedures</i>		
Magnetic resonance imaging head	1	0
<i>Heart rate and pulse investigations</i>		
Heart rate	3	0
Heart rate irregular	1	0
<i>Mineral and electrolyte analyses</i>		
Blood iron decreased	1	0
Blood iron increased	1	0
<i>Physical examination procedures and organ system status</i>		
Body temperature	4	0
Body temperature decreased	2	0
Body temperature fluctuation	1	0
Body temperature increased	7	0
<i>Pituitary analyses anterior</i>		
Blood thyroid stimulating hormone increased	1	0
<i>Urinalysis NEC</i>		
Crystal urine	1	0
<i>Vascular tests NEC (incl blood pressure)</i>		
Blood pressure increased	1	0
<i>White blood cell analyses</i>		
White blood cell count	1	0
<b>Investigations SOC TOTAL</b>	<b>25</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

<b>Reaction Name</b>	<b>Total</b>	<b>Fatal</b>
<b>Metabolic disorders</b>		
<i>Appetite disorders</i>		
Decreased appetite	13	0
<i>Total fluid volume decreased</i>		
Dehydration	4	0
<i>Total fluid volume increased</i>		
Fluid retention	1	0
<b>Metabolic disorders SOC TOTAL</b>	<b>18</b>	<b>0</b>



## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022  
Earliest Reaction Date: 21-Mar-2020

Data Lock Date: 20-Apr-2022 18:30:04  
MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Muscle &amp; tissue disorders</b>		
<i><b>Arthropathies NEC</b></i>		
Arthritis	2	0
<i><b>Bone disorders NEC</b></i>		
Medial tibial stress syndrome	1	0
<i><b>Bone related signs and symptoms</b></i>		
Bone pain	4	0
<i><b>Cartilage disorders</b></i>		
Costochondritis	1	0
<i><b>Joint related disorders NEC</b></i>		
Temporomandibular joint syndrome	1	0
<i><b>Joint related signs and symptoms</b></i>		
Arthralgia	65	0
Joint stiffness	2	0
Joint swelling	6	0
<i><b>Muscle pains</b></i>		
Fibromyalgia	1	0
Myalgia	62	0
<i><b>Muscle related signs and symptoms NEC</b></i>		
Muscle fatigue	5	0
Muscle spasms	11	0
Muscle tightness	1	0
Muscle twitching	1	0
<i><b>Muscle weakness conditions</b></i>		
Muscular weakness	6	0
<i><b>Musculoskeletal and connective tissue conditions NEC</b></i>		
Mobility decreased	2	0
Musculoskeletal stiffness	10	0
<i><b>Musculoskeletal and connective tissue pain and discomfort</b></i>		
Back pain	12	0
Limb discomfort	10	0
Musculoskeletal chest pain	1	0
Musculoskeletal discomfort	1	0
Neck pain	11	0
Pain in extremity	70	0
<i><b>Rheumatoid arthropathies</b></i>		
Rheumatoid arthritis	1	0
<i><b>Tendon disorders</b></i>		
Tendon pain	1	0
Tendonitis	2	0
Tenosynovitis	1	0
<b>Muscle &amp; tissue disorders SOC TOTAL</b>	<b>291</b>	<b>0</b>

# Case Series Drug Analysis Print

## Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Neoplasms</b>		
<i>Breast and nipple neoplasms malignant</i>		
Breast cancer	1	0
<b>Neoplasms SOC TOTAL</b>	<b>1</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022  
Earliest Reaction Date: 21-Mar-2020

Data Lock Date: 20-Apr-2022 18:30:04  
MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Nervous system disorders</b>		
<i>Abnormal reflexes</i>		
Areflexia	1	0
<i>Acute polyneuropathies</i>		
Guillain-Barre syndrome	1	0
<i>Central nervous system haemorrhages and cerebrovascular accidents</i>		
Cerebrovascular accident	4	1
<i>Coordination and balance disturbances</i>		
Balance disorder	1	0
Dysstasia	1	0
<i>Cortical dysfunction NEC</i>		
Aphasia	1	0
<i>Disturbances in consciousness NEC</i>		
Lethargy	11	0
Loss of consciousness	4	0
Somnolence	4	0
Syncope	8	0
<i>Dyskinesias and movement disorders NEC</i>		
Movement disorder	1	0
<i>Facial cranial nerve disorders</i>		
Bell's palsy	3	0
<i>Headaches NEC</i>		
Cluster headache	1	0
Headache	235	0
Sinus headache	2	0
Tension headache	7	0
Thunderclap headache	1	0
<i>Memory loss (excl dementia)</i>		
Memory impairment	2	0
<i>Mental impairment (excl dementia and memory loss)</i>		
Cognitive disorder	1	0
Disturbance in attention	3	0
<i>Migraine headaches</i>		
Migraine	23	0
Migraine without aura	1	0
<i>Multiple sclerosis acute and progressive</i>		
Multiple sclerosis	1	0
<i>Neurological signs and symptoms NEC</i>		
Dizziness	64	0
Dizziness postural	4	0
Head discomfort	1	0
Neurological symptom	2	0
Presyncope	2	0
<i>Paraesthesias and dysaesthesias</i>		
Burning sensation	4	0
Hypoaesthesia	17	0
Paraesthesia	27	0
<i>Parkinson's disease and parkinsonism</i>		
Freezing phenomenon	1	0
<i>Seizures and seizure disorders NEC</i>		
Epilepsy	2	0
<i>Sensory abnormalities NEC</i>		
Ageusia	1	0
Dysgeusia	5	0

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022  
 Earliest Reaction Date: 21-Mar-2020

Data Lock Date: 20-Apr-2022 18:30:04  
 MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Nervous system disorders</b> <small>Nervous system disorders cont'd</small>		
Neuralgia	1	0
Taste disorder	5	0
<b><i>Speech and language abnormalities</i></b>		
Dysarthria	1	0
<b><i>Transient cerebrovascular events</i></b>		
Transient ischaemic attack	5	0
<b><i>Tremor (excl congenital)</i></b>		
Tremor	34	0
<b><i>Trigeminal disorders</i></b>		
Trigeminal neuralgia	1	0
<b>Nervous system disorders SOC TOTAL</b>	<b>494</b>	<b>1</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

<b>Reaction Name</b>	<b>Total</b>	<b>Fatal</b>
<i>Device malfunction events NEC</i>		
Thrombosis in device	2	0
<b>null SOC TOTAL</b>	<b>2</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Psychiatric disorders</b>		
<i><b>Anxiety symptoms</b></i>		
Agitation	1	0
Anxiety	6	0
Stress	2	0
<i><b>Cognitive and attention disorders and disturbances NEC</b></i>		
Mental fatigue	2	0
<i><b>Confusion and disorientation</b></i>		
Confusional state	3	0
Disorientation	1	0
<i><b>Deliria</b></i>		
Delirium	2	0
<i><b>Depressive disorders</b></i>		
Depression	3	0
<i><b>Disturbances in initiating and maintaining sleep</b></i>		
Insomnia	8	0
<i><b>Dyssomnias</b></i>		
Poor quality sleep	4	0
<i><b>Emotional and mood disturbances NEC</b></i>		
Anger	1	0
Irritability	2	0
<i><b>Fear symptoms and phobic disorders (incl social phobia)</b></i>		
Fear	1	0
<i><b>Hallucinations (excl sleep-related)</b></i>		
Hallucination, visual	1	0
<i><b>Increased physical activity levels</b></i>		
Restlessness	1	0
<i><b>Mood alterations with depressive symptoms</b></i>		
Depressed mood	1	0
Tearfulness	1	0
<i><b>Mood disorders NEC</b></i>		
Listless	1	0
<i><b>Parasomnias</b></i>		
Abnormal dreams	2	0
Nightmare	3	0
<i><b>Somatic symptom disorders</b></i>		
Habit cough	1	0
<i><b>Stress disorders</b></i>		
Catastrophic reaction	1	0
<b>Psychiatric disorders SOC TOTAL</b>	<b>48</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

<b>Reaction Name</b>	<b>Total</b>	<b>Fatal</b>
<b>Renal &amp; urinary disorders</b>		
<i>Bladder and urethral symptoms</i>		
Dysuria	1	0
Pollakiuria	2	0
Urinary incontinence	1	0
<i>Bladder neoplasms</i>		
Bladder cyst	1	0
<i>Renal failure and impairment</i>		
Acute kidney injury	1	0
<b>Renal &amp; urinary disorders SOC TOTAL</b>	<b>6</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Reproductive &amp; breast disorders</b>		
<i><b>Breast signs and symptoms</b></i>		
Breast pain	3	0
Breast tenderness	1	0
<i><b>Erection and ejaculation conditions and disorders</b></i>		
Erectile dysfunction	1	0
Organic erectile dysfunction	1	0
<i><b>Menopausal effects NEC</b></i>		
Menopausal symptoms	1	0
<i><b>Menstruation and uterine bleeding NEC</b></i>		
Dysmenorrhoea	1	0
Intermenstrual bleeding	1	0
Menstrual disorder	3	0
Menstruation irregular	5	0
<i><b>Menstruation with decreased bleeding</b></i>		
Amenorrhoea	2	0
Hypomenorrhoea	1	0
Menstruation delayed	5	0
<i><b>Menstruation with increased bleeding</b></i>		
Heavy menstrual bleeding	10	0
Menometrorrhagia	1	0
Polymenorrhoea	1	0
<i><b>Ovarian and fallopian tube cysts and neoplasms</b></i>		
Polycystic ovaries	1	0
<i><b>Ovarian and fallopian tube disorders NEC</b></i>		
Ovulation pain	1	0
<i><b>Pelvis and broad ligament disorders NEC</b></i>		
Adnexa uteri pain	1	0
<i><b>Scrotal disorders NEC</b></i>		
Scrotal pain	1	0
<i><b>Vulvovaginal disorders NEC</b></i>		
Vaginal haemorrhage	1	0
<i><b>Vulvovaginal signs and symptoms</b></i>		
Vulvovaginal burning sensation	1	0
<b>Reproductive &amp; breast disorders SOC TOTAL</b>	<b>43</b>	<b>0</b>



## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022  
Earliest Reaction Date: 21-Mar-2020

Data Lock Date: 20-Apr-2022 18:30:04  
MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Respiratory disorders</b>		
<i>Breathing abnormalities</i>		
Dyspnoea	22	0
Hypopnoea	1	0
<i>Bronchospasm and obstruction</i>		
Bronchospasm	1	0
Wheezing	2	0
<i>Coughing and associated symptoms</i>		
Cough	8	0
<i>Nasal disorders NEC</i>		
Epistaxis	7	0
<i>Parenchymal lung disorders NEC</i>		
Atelectasis	1	0
<i>Pharyngeal disorders (excl infections and neoplasms)</i>		
Tonsillar hypertrophy	1	0
<i>Pneumothorax and pleural effusions NEC</i>		
Pleural effusion	1	0
<i>Pulmonary thrombotic and embolic conditions</i>		
Pulmonary embolism	5	0
<i>Upper respiratory tract signs and symptoms</i>		
Catarrh	1	0
Dry throat	1	0
Dysphonia	1	0
Oropharyngeal pain	9	0
Rhinorrhoea	2	0
Sinus pain	2	0
Sneezing	1	0
Throat irritation	2	0
<b>Respiratory disorders SOC TOTAL</b>	<b>68</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Skin disorders</b>		
<b><i>Angioedemas</i></b>		
Angioedema	1	0
<b><i>Apocrine and eccrine gland disorders</i></b>		
Cold sweat	3	0
Hyperhidrosis	27	0
Miliaria	1	0
Night sweats	4	0
<b><i>Bullous conditions</i></b>		
Blister	3	0
Erythema multiforme	1	0
<b><i>Dermal and epidermal conditions NEC</i></b>		
Pain of skin	2	0
Papule	1	0
Skin burning sensation	2	0
Skin odour abnormal	1	0
Skin reaction	1	0
Skin warm	3	0
<b><i>Dermatitis and eczema</i></b>		
Dermatitis allergic	3	0
Eczema	1	0
<b><i>Erythemas</i></b>		
Erythema	9	0
<b><i>Exfoliative conditions</i></b>		
Skin exfoliation	1	0
<b><i>Pruritus NEC</i></b>		
Pruritus	26	0
<b><i>Purpura and related conditions</i></b>		
Purpura	1	0
<b><i>Rashes, eruptions and exanthems NEC</i></b>		
Rash	27	0
Rash erythematous	3	0
Rash macular	4	0
Rash pruritic	2	0
Rash vesicular	1	0
<b><i>Rosaceas</i></b>		
Rosacea	1	0
<b><i>Skin haemorrhages</i></b>		
Haemorrhage subcutaneous	1	0
<b><i>Skin vasomotor conditions</i></b>		
Livedo reticularis	1	0
<b><i>Urticarias</i></b>		
Urticaria	6	0
<b>Skin disorders SOC TOTAL</b>	<b>137</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Surgical &amp; medical procedures</b>		
<i>Immunisations</i>		
COVID-19 immunisation	1	0
Immunisation	3	0
<i>Therapeutic procedures NEC</i>		
Catheter management	1	0
<i>Vascular therapeutic procedures NEC</i>		
Clamping of blood vessel	1	0
<b>Surgical &amp; medical procedures SOC TOTAL</b>	<b>6</b>	<b>0</b>

## Case Series Drug Analysis Print

### Name: COVID-19 vaccine AstraZeneca Analysis Print

Report Run Date: 04-May-2022

Data Lock Date: 20-Apr-2022 18:30:04

Earliest Reaction Date: 21-Mar-2020

MedDRA Version: MedDRA 24.1

Reaction Name	Total	Fatal
<b>Vascular disorders</b>		
<i><b>Aortic infections and inflammations</b></i>		
Aortitis	1	0
<i><b>Arterial infections and inflammations</b></i>		
Arteritis	1	0
<i><b>Circulatory collapse and shock</b></i>		
Circulatory collapse	2	0
<i><b>Haemorrhages NEC</b></i>		
Haematoma	1	0
Haemorrhage	4	0
<i><b>Non-site specific embolism and thrombosis</b></i>		
Thrombosis	5	0
<i><b>Non-site specific vascular disorders NEC</b></i>		
Vascular pain	1	0
<i><b>Peripheral embolism and thrombosis</b></i>		
Blue toe syndrome	1	0
Deep vein thrombosis	4	0
<i><b>Peripheral vascular disorders NEC</b></i>		
Cyanosis	1	0
Flushing	1	0
Hot flush	14	0
<i><b>Peripheral vasoconstriction, necrosis and vascular insufficiency</b></i>		
Peripheral coldness	7	0
Raynaud's phenomenon	1	0
<i><b>Vasculitides NEC</b></i>		
Vasculitis	2	0
<b>Vascular disorders SOC TOTAL</b>	<b>46</b>	<b>0</b>
<b>TOTAL REACTIONS FOR DRUG</b>	<b>2302</b>	<b>1</b>
<b>TOTAL REPORTS</b>	<b>625</b>	
<b>TOTAL FATAL OUTCOME REPORTS</b>		<b>1</b>